Adam Brown Part 4, Most Exciting Thing at ADA 2018

In part 4 of this Exclusive Interview, Adam Brown talks with Diabetes in Control Publisher Steve Freed about his thoughts on further CGM development and the advancements in the closed loop system.

Adam Brown, is senior editor and columnist at diaTribe.org, and head of Diabetes Technology & Connected Care at Close Concerns.

Transcript of this video segment:

Freed: So, what’s the most exciting thing that you’ve seen here that you feel is going to have a great future?

Brown: Couple of things. One is just closed loop systems, I think where there’s one on the market, the Medtronix 670G. A lot of people like it. Some people, it’s not a fit for them. And we’re seeing a slew of commercial products starting to make it close to pivotal studies or getting into pivotal studies. Insulet presented exciting data here on their OmniPod Horizon which looks really great. And I think we’re just going to see more and more of – Tandem got approval for their Basal-IQ on Thursday which is a predictive low glucose suspend system and they actually got it with the Dexcom G6. So, FDA made a really — even though it started with G5, FDA said, “You know what, it’s similar to G6. We’ll approve it with G6.” And so, now we’re not going to see this annoy lag time between the sensors. So, I think closed loop is going to be really exciting for people who are able to access it and willing to do that. And then, just seeing CGM continue to get better and better in terms of the — not only the hardware that you wear on your body but actually the software around it, and the prompts, and the analysis, and also getting it to providers. So, one of the things we saw approved earlier this week was the DreaMed Gluco Advisor Pro. You come in as a person with diabetes. You’re wearing a pump and a CGM. The software crunches all your data, gives the provider recommendations on how to change the pump’s settings to optimize your basal carb ratio, insulin sensitivity factor, and then the providers sends it to the patient’s mobile app, and that’s it. And so, I think for people about five, ten minutes with a patient, being able to get that kind of decision support, it’s going to be awesome.

Freed: What was the name of that?

Brown: That’s the DreaMed Gluco Advisor Pro.

Freed: And that’s from who?

Brown: It’s made — the algorithm is from DreaMed, Gluco is commercializing it.

Freed: Oh, Gluco.

Brown: Yeah, yeah, yeah. And it was cleared on Monday, so they’re going to start rolling it out, I think, later this summer.

Freed: So, CGM has basically changed the world of diabetes. And you had mentioned, which I think is kind of curious, using a CGM for prediabetes. And it only makes sense that if a person was to wear it with prediabetes, they would change their eating habits. I mean, without a doubt — because most people would think that corn is a vegetable and it’s good for you. (Laughs)

Brown: Totally. Orange juice, it’s fruit, right? (Laughs)

Freed: People need a better understanding because when it comes to Diabetes in Control it’s all about knowledge and education.

Brown: Totally.

Freed: So, where you get cancer, hopefully you get a good oncologist and you can cure it. With diabetes, there’s no medicine in the world that’s going to take care of your blood sugars and you can eat whatever you want.

Brown: Exactly.

Return to the main page.